

# Marijuana and the Pediatric Population

Sadhana Dharmapuri, MD,<sup>a,b</sup> Kathleen Miller, MD, FAAP,<sup>c</sup> Jonathan D. Klein, MD, MPH<sup>a</sup>

Cannabinoids, the psychoactive compounds in marijuana, are one of the most commonly used substances in the United States. In this review, we summarize the impact of marijuana on child and adolescent health and discuss the implications of marijuana use for pediatric practice. We review the changing epidemiology of cannabis use and provide an update on medical use, routes of administration, synthetic marijuana and other novel products, the effect of cannabis on the developing brain, other health and social consequences of use, and issues related to marijuana legalization.

## abstract

### EPIDEMIOLOGY

Cannabis is one of the most commonly used psychoactive substances in the United States.

In recent years, the increase in potency of cannabis (which includes a sixfold to sevenfold increase in tetrahydrocannabinol [THC] content), the proliferation of alternative forms of cannabis for consumption, and electronic vapor device use pose challenges to both public health and clinical practice.<sup>1</sup> In 2017, the Centers for Disease Control and Prevention Youth Risk Behavior Survey found that 19.8% of youth of high school age reported past-month marijuana use, and 35.6% had ever tried marijuana,<sup>2</sup> down from a peak rate of 47.1% in 1997. Synthetic marijuana use also declined, from 9% in 2015 to 6% in 2017. Although use has declined, youth who use marijuana often engage in other risk-taking behaviors that impact their overall well-being; for example, 13% of youth reported driving after using marijuana.<sup>2</sup> In 2017, ever use of marijuana among Black or African American (42.8%) and Hispanic (42.2%) students was higher than among white (32.0%) students. The prevalence of current marijuana use was also higher among gay, lesbian, and bisexual (30.6%) students compared with heterosexual (19.1%) and “not

sure” (18.9%) students. Older students had a higher prevalence of current marijuana use, with 13.1% of ninth-grade students, 18.7% of 10th-grade students, 22.6% of 11th-grade students, and 25.7% of 12th-grade students reporting current use. With legalization, marijuana use during pregnancy has become more common, with 7.1% of pregnant women reporting marijuana use in the past month and 3.1% reporting daily use.<sup>3</sup>

Only one recent study has examined the relationship between the availability of legal medical marijuana and use in adolescents. This cross-sectional survey of students whose school was within a 5-mile radius from a medical dispensary did not find increased use of marijuana among these youth.<sup>4</sup> More studies are needed to determine the effect of proximity to medical dispensaries on marijuana use.

National surveys have found that youth who engaged in marijuana use in later teen-aged years (>17) were less likely to develop substance use disorders compared with those who started earlier. Positive attitudes toward school, parental monitoring, and strong disapproval of peer’s substance abuse were found to be protective factors against substance use disorder.<sup>3</sup>

<sup>a</sup>Department of Pediatrics, University of Illinois at Chicago, Chicago, Illinois; <sup>b</sup>Department of Pediatrics, Cook County Health and Hospitals System, Chicago, Illinois; and <sup>c</sup>Adolescent Medicine Fellowship Program, Division of General Pediatrics and Adolescent Health, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota

Drs Dharmapuri and Klein drafted the initial manuscript and reviewed and revised the manuscript; Dr Miller reviewed and revised the manuscript; and all authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

**DOI:** <https://doi.org/10.1542/peds.2019-2629>

Accepted for publication Feb 27, 2020

Address correspondence to Jonathan D. Klein, MD, MPH, Department of Pediatrics, University of Illinois at Chicago, 840 S Wood St, MC 856, Chicago, IL 60612. E-mail: jonklein@uic.edu

PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).

Copyright © 2020 by the American Academy of Pediatrics

**FINANCIAL DISCLOSURE:** The authors have indicated they have no financial relationships relevant to this article to disclose.

**FUNDING:** No external funding.

**POTENTIAL CONFLICT OF INTEREST:** The authors have indicated they have no potential conflicts of interest to disclose.

**To cite:** Dharmapuri S, Miller K, Klein JD. Marijuana and the Pediatric Population. *Pediatrics*. 2020; 146(2):e20192629

## PHARMACOLOGY

Although a comprehensive review of pharmacokinetics and pharmacodynamics is beyond the scope of this review, it is helpful to summarize the kinetics of cannabis and common cannabis extracts and concentrates to aid clinicians in better understand the effects of various forms of cannabis on youth.

Cannabis occurs naturally as a plant, leading to production of cannabis products made of dried leaves, oils, and concentrates. Many cannabis products contain numerous substances, including terpenes, flavonoids, alkaloids, and >100 cannabinoids. There is no standardized form of cannabis; the presence and relative amount of various substances may differ between cannabis extracts as well as between products designed to be smoked or vaporized.<sup>5</sup>

The endocannabinoid system, composed of endocannabinoids and cannabinoid receptors, is widely distributed in the brain and spinal cord. This system has a regulatory role in many physiologic processes, including inflammation, appetite regulation, immune function, cardiovascular function, neural development, pain, the sleep and wake cycle, psychiatric disease, and others. Endocannabinoids, endogenous lipids with precursors that are present in lipid membranes, interact with endocannabinoid receptors CB1 and CB2.<sup>6</sup> Being lipophilic, cannabinoids are rapidly absorbed.

Phytocannabinoids, plant-derived cannabinoids, can be categorized into several classes;  $\delta$ -9 tetrahydrocannabinol (generally known as THC) and cannabidiol (generally known as CBD) are the most abundant and studied forms. THC is considered the main psychoactive component of the plant.

Phytocannabinoids affect users through their interactions with

endocannabinoid receptors CB1 and CB2 and related binding proteins in the nervous system. CB1 receptors are found in the central nervous system on neurons in the prefrontal cortex, basal ganglia, hippocampus, amygdala, hypothalamus, and cerebellum. CB1 receptors are also found in smooth muscle, myocardium, adipocytes, and preganglionic sympathetic neurons. The CB2 receptor is expressed in peripheral blood mononuclear cells as well as in the smooth muscle, myocardium, and vascular endothelium.

THC acts as an agonist at CB1 and CB2 receptor sites. Binding the receptor site reduces neurotransmission, producing effects such as impairments in learning, memory, spatial orientation, and attention and physiologic effects such as tachycardia. THC also has analgesic and antiinflammatory effects.<sup>7</sup> CBD has weak affinity for CB1 receptors, does not interact directly with CB2 receptors, and does not produce the intoxicating effects of THC ingestion.

There is considerable variation in the pharmacokinetic profiles of THC and CBD between users, by cannabis dosages and forms, with acute and chronic use, and by route of administration. Smoked and/or vaporized cannabis has a rapid onset of action, with peak levels achieved within 10 minutes and greater bioavailability compared with oral ingestion. Bioavailability of THC ranges from 2% to 56% with smoked or vaporized cannabis and from 11% to 45% with smoked CBD. Oral absorption has more variability and lower bioavailability. The acute effects of ingested cannabis may last for several hours, depending on concentration, formulation of the product, and gastrointestinal motility, vascularity, and blood flow.<sup>5</sup> Distribution of THC is time dependent and is immediate with absorption into fat tissue and highly perfused organs. Elimination half-life also

varies. THC has a fast initial half-life (6 minutes) and a longer terminal half-life (22 hours). Chronic users have longer elimination times, with THC present for >24 hours. CBD has a long terminal half-life, from 33 hours to 5 days, depending on the amount used.

Metabolism of THC occurs mainly in the liver by the cytochrome P450 system. CBD inhibits cytochrome oxidases; thus, it may interfere with other commonly used medications. CBD has a regulatory effect on THC, with the potential to decrease some adverse effects (ie, tachycardia, anxiety, and sedation).<sup>5</sup>

Drug interactions have been noted with the use of cannabis. For example, cannabis containing THC has been associated with increased rates of psychotic relapse and treatment failure.<sup>8</sup> In an animal study, THC had a negative effect on the efficacy of risperidone.<sup>9</sup> Drug interactions noted for CBD included increases in serum levels of antiepileptic drugs, resulting in sedation.<sup>8</sup>

Synthetic cannabinoids (SCs) are biochemically similar to THC and are used for both medicinal purposes and recreational purposes. Dronabinol is a schedule III drug and is approved for the treatment of nausea and vomiting associated with chemotherapy and for the treatment of anorexia and weight loss due to AIDS. Dronabinol typically comes in 2.5-, 5-, and 10-mg tablets and is taken 1 or 2 times a day in doses of up to 40 mg/day. Nabilone, a schedule II SC, comes in 0.25-, 0.5-, and 1-mg tablets, is prescribed up to 3 times a day, and is approved for chemotherapy associated nausea and vomiting.<sup>8</sup>

## MEDICAL USES OF CANNABIS

The Drug Enforcement Agency has classified cannabis as a schedule I drug. This precludes cannabis being considered for legal medical uses, and therefore it is also not regulated,

except for dronabinol, nabilone, and CBD. Dronabinol and nabilone are SCs. CBD is a plant-derived product approved for use in children as a second-line treatment of 2 conditions: Lennox-Gastaut syndrome and Dravet syndrome.<sup>10</sup>

The medical conditions that CBD can be legally used for vary by state. Most studies examining CBD treatment of various conditions (cachexia or wasting, AIDS, cancer pain, etc) have been on adults. According to a National Academy of Sciences review, cannabis and cannabinoids are effective for the treatment of chronic pain in adults, are effective as antiemetics for the treatment of chemotherapy-induced nausea and vomiting, and are effective for improving spasticity in adults with multiple sclerosis.<sup>11</sup>

Although some benefits of marijuana for treatment of behavioral conditions have been reported in animal studies, there are few studies in humans. In 2 case reports, authors noted benefits from dronabinol in children: one report of a 6-year-old boy with autism and the other of an adolescent with self-injurious behaviors.<sup>12,13</sup>

The use of medical cannabis for treatment of inflammatory bowel disease (IBD) has increased in recent years. There is some evidence that cannabis may have antiinflammatory properties, improve IBD symptoms, and improve quality of life. However, in adults, CBD did not improve IBD pathology, and use of cannabis in pediatric IBD is not recommended.<sup>14</sup>

In a systematic review of cannabis for treatment of seizures, 4 high-quality randomized controlled studies found a reduction in seizures with the use of Epidiolex, a CBD product US Food Drug Administration (FDA) approved for treatment of Dravet syndrome and Lennox-Gastaut syndrome. Outcomes using other cannabis preparations were inconclusive.<sup>15</sup> A few small, nonrandomized studies have suggested benefits from CBD use in

other seizure disorders, including Sturge-Weber epilepsy and febrile infection-related epilepsy; however, there is limited evidence for use in these disorders.<sup>16,17</sup> Limitations of these studies include the following: use of other CBD products were not compared with use of Epidiolex, treatment time was short, studies had small samples, and CBD was added as an adjunct rather than as a first-line treatment.<sup>15</sup> CBD was noted to provide seizure-free activity in a small proportion of children with Dravet syndrome. However, the authors suggest that a reduction in seizures may be a more realistic expectation with use of CBD rather than seizure-free activity.<sup>15</sup>

Parents and providers should be aware that there are limited studies addressing CBD use in children or adolescents and that there often is cross-contamination of CBD products with THC. Thus, CBD products may lead to positive urine drug test results for THC. This is especially important for adolescents required to take drug tests for sports or employment. Additionally, CBD products are unregulated, except for those drugs that are FDA approved.

#### DUAL USE OF CANNABIS AND TOBACCO

Population-based surveys from the 1990s revealed that most cannabis users were co-users of tobacco. Until the recent electronic cigarette (e-cigarette) or JUUL epidemic, there had been a steady decrease in self-report of tobacco use in youth. However, youth who smoke tobacco remain more likely to report marijuana use.<sup>18,19</sup> Co-users in this study had lower academic performance compared with cannabis-only users and were more likely to be male than female. In this study, the authors speculated that the increased use of cannabis was associated with normative behavior, whereas tobacco use was perceived as riskier behavior. Another study

examining the co-use of tobacco and marijuana found that marijuana use was associated with greater nicotine addiction among adolescent smokers and that compulsion to smoke and preference to smoke were associated with marijuana use.<sup>20</sup> These authors hypothesized that smoking cues for one substance may trigger cravings for the other substance and lead to increased use in adulthood.<sup>20,21</sup> They suggest that the association of marijuana use with tobacco use should be considered when developing prevention programs for both substances. Alcohol co-use with marijuana has also been identified in several studies. Alcohol has adverse effects on the developing adolescent brain similar to those for marijuana, such as poorer attention and executive functioning, heightened emotional reactivity, and poorer distress tolerance.<sup>22</sup> A longitudinal study examining the effect of alcohol use on marijuana use found that alcohol was a significant predictor of cannabis initiation within a year. In their study, Terry-McElrath et al<sup>23</sup> found that co-use of marijuana and alcohol was associated with unsafe driving. They suggested that co-use of alcohol and marijuana in the context of driving should be explored when providing preventive care.

The *Bright Futures: Guidelines for Health Supervision of Infants, Children and Adolescents, Fourth Edition*<sup>24</sup> highlights health issues to be screened for at health maintenance visits. Tobacco, alcohol, and drug risk assessment is recommended throughout the adolescent years.<sup>24</sup> The American Academy of Pediatrics (AAP) policy statement on substance abuse and prevention suggests that pediatricians become familiar with substance abuse screening.<sup>25</sup> The AAP recommends using short validated screeners to determine youth at risk.<sup>25</sup> One validated screener is the CRAFFT (car, relax, alone, forget, family or friends, and trouble), which screens to identify

youth aged 12 to 21 years old at risk for alcohol or substance use, driving or riding risk, and substance use disorder. CRAFFT 2.1 is an updated version of that incorporates opening questions that quantify the amount of use within the past 12 months, and CRAFFT + N includes an opening question on tobacco, including smoking and/or vaping use.<sup>26</sup> The tool is scored as low, medium, and high risk. CRAFFT 2.1 includes recommendations on how to discuss risk and how to contract for safe rides, which has been shown to decrease the risk of adolescents riding in a car with someone who has been drinking or using drugs.<sup>26</sup>

## MARIJUANA AND PREGNANCY

Marijuana is one of the most commonly used illicit substances in women, and the estimated prevalence of use among pregnant women in the United States ranges between 3% and 16%.<sup>27</sup> From 2002 to 2014 past-month marijuana use among pregnant women increased by 62%.<sup>28</sup> Legalization has increased accessibility and strengthened advocacy for its use, which may contribute to the increased use and perceived safety for pregnant women. Pregnant women are using marijuana for several reasons. In a Canadian survey, researchers found that 77% of medicinal cannabis use was for treatment of nausea. Half of the women surveyed reported using marijuana to treat poor appetite, pain, insomnia, or mood disorders (depression and anxiety).<sup>28</sup> Use of cannabinoids during pregnancy has led to health concerns related to fetal development because exogenous cannabinoids containing THC cross the fetal-placental barrier in humans.<sup>29-31</sup>

The endocannabinoid system plays a major role in fetal development, and the concentration of CB1 receptors is higher in fetal brains than in adults.<sup>32</sup> THC binds to the CB1 receptor

instead of endocannabinoids, leading to various neurodevelopmental changes. Animal studies of prenatal THC exposure provide strong evidence for these adverse effects.<sup>33</sup> In a review of several studies on prenatal marijuana use, investigators found a dose-response effect on fetal growth; increased use was associated with decreased growth.<sup>34</sup> It was unclear whether prenatal exposure had an effect on preterm births. In a meta-analysis of 31 studies on marijuana use during pregnancy, investigators found that maternal marijuana use and concomitant tobacco exposure contributed to adverse neonatal outcome.<sup>34-36</sup> Marijuana exposure has also been associated with NICU admissions as well as with increased respiratory and neurologic infections and hematologic morbidity.<sup>34</sup>

Animal studies revealed that even low levels of exposure to marijuana have adverse neurologic effects.<sup>37</sup> In a recent systematic review examining 7 longitudinal studies on the effects of prenatal exposure on neuropsychological function in children, investigators found varied results between the association of prenatal exposure to marijuana and a child's neuropsychological development at ages 1 to 11 years. The majority of studies demonstrated a negative impact of marijuana during pregnancy, including deficits in neuropsychological functioning, decreased attention, memory problems, and poor impulse control.<sup>37</sup> However, there were mixed results between studies, and the authors acknowledged that there may be confounding biases.

Another area of interest has been the relationship between breastfeeding and maternal marijuana use. Cannabis concentration in breast milk is related to the maternal dose ingested and frequency of ingestion.<sup>38-40</sup> In 2 studies, authors investigated outcomes for infants exposed to cannabis from

breastfeeding. In 1 study, the authors found an association between marijuana detected in breast milk and decreased motor development at 1 year; however, the authors noted that this result could have been confounded by the use of marijuana during pregnancy. In the other study, authors compared breastfed infants exposed to marijuana and those not exposed to marijuana; these authors noted no differences in motor or cognitive skills at 1 year.<sup>38,39</sup>

Human studies on maternal marijuana use have been limited, and most have been observational or retrospective, relying on patient self-report. These studies have been confounded by polysubstance abuse and had small sample sizes. At this time, a causal relationship cannot be established. However, because of the paucity of research, it is recommended that women refrain from marijuana use during pregnancy and breastfeeding. The American College of Obstetrics and Gynecology and the AAP recommend that breastfeeding mothers refrain from marijuana use.<sup>41,42</sup> Standard of care for prenatal and postnatal visits should include screening for drug use, including marijuana use. Clinicians should be aware that women may also seek information on marijuana use in pregnancy and breastfeeding from other sources. Clinicians should try to ensure that patients have access to current evidence-based information about marijuana use.

## ADVERSE EFFECTS FROM CANNABIS USE

The adverse effects of cannabis use are well documented. Adverse effects include distorted perception, poor concentration, psychosis, excessive vomiting, and addiction.

Endogenous cannabinoids have an important role in the control of neural circuits and structures in the prefrontal cortex and the hippocampus. During adolescence,



these circuits mature and regulate attention, executive functioning, and memory. Studies have revealed that the development and maturation of these circuits can be affected by cannabis, causing impairment in neurocognitive functioning.<sup>43,44</sup> THC is a lipophilic substance with a long half-life that becomes distributed in various tissue, including the brain's myelin. It is released back into the bloodstream over the course of 5 to 95 days in individuals with heavy, regular use, meaning that neurodevelopmental changes can continue to occur for weeks to months after consumption.<sup>45,46</sup> Of note, manufactured and synthetic marijuana products may have higher THC concentrations than naturally occurring products, which can lead to more intense and longer-lasting effects.

In a longitudinal study by Meier et al,<sup>45</sup> cannabis use >20 years was associated with neuropsychological decline, with worsening effects for long-term users. In another study, authors explored neurocognitive measures in adolescents with recent cannabis use disorder who were now abstaining and also found that younger onset was associated with lower overall neurocognitive function. Similarly, Meier et al<sup>45</sup> found persistent neurocognitive changes 1 year after cessation of cannabis use.

In a recent longitudinal study on marijuana use and adolescent brain development, researchers found that cannabis use had adverse effects on IQ and executive functioning.<sup>46</sup> This cross-sectional longitudinal study revealed differences in resting-state networks known to mediate executive functioning (left dorsolateral prefrontal cortex) and regulatory control (anterior cingulate cortex). Marijuana use was associated with declines in neural connectivity over time, especially in adolescents with cannabis use disorder.<sup>46</sup> In an Australian longitudinal study, authors

found that individuals who used before age 17 years old had a reduced odds of high school graduation and degree completion compared with nonusers. These individuals were more likely to have cannabis use disorder, were more likely to use other illicit substances, and had more suicide attempts.<sup>47</sup>

Animal studies of cannabis use and psychosis have suggested a remodeling of brain structure due to effects on the endocannabinoid system. These changes are similar to changes seen in schizophrenia.<sup>48</sup> In a recent study by Di Forti et al,<sup>49</sup> the authors found that daily marijuana use and high-potency marijuana (THC content >10%) are the strongest independent predictors of whether an individual will have a psychotic episode. Initiation of marijuana use by age 15 years slightly increased the odds of having a psychotic episode, but this was not independent of potency and frequency of use. Individuals with daily use had a 3.2 times higher likelihood of developing psychosis compared with nonusers. Individuals who used high-potency marijuana were 1.6 times more likely to develop psychosis compared with nonusers.<sup>49</sup> Individuals who had both daily use and high-potency use were almost 5 times as likely to develop psychosis compared with nonusers. Further studies exploring frequency and potency of use and gene expression may help elucidate the neurobiology behind the development of psychosis due to cannabis. Physicians should be aware of the increasing potency of legal marijuana products; for example, the average THC content of marijuana sold legally in Colorado is ~18%.

Marijuana use has also been found to be linked to an increase in use of prescription pain medication (opioids). Individuals who used marijuana had a 2.78 increase risk of having an opioid use disorder.<sup>50</sup> Other

drugs associated with marijuana use include stimulants, cocaine, and injection drugs.<sup>51</sup> In 2018, the Insurance Institute for Highway Safety and the Highway Loss Data Institute reported an increase in motor vehicle crashes in states that had legalized marijuana use. In one study comparing perceptions of impaired driving after alcohol use, young adults felt that marijuana use was safer than alcohol use for driving.<sup>52</sup> However, study participants did not feel as knowledgeable about the effects of marijuana on driving.

Toxicity from consumption of marijuana has been documented in several case studies. Most individuals who experience toxicity have been exposed to high concentrations of cannabinoids. These individuals can experience adverse health effects, including sedation, respiratory depression, hyperemesis, and cardiotoxicity.

Marijuana use has also been associated with the positive health effect of decreasing nausea. However, chronic use can cause a paradoxical effect, leading to hyperemesis. Patients typically present with cyclic vomiting, nausea, and epigastric pain. Interestingly, these symptoms are often reported to be relieved by hot showers.<sup>53-55</sup> Capsaicin has also been a successful treatment of hyperemesis.<sup>55</sup>

A systematic review of unintentional cannabis ingestion in children and adolescents revealed rates increasing in states that had legalized marijuana.<sup>56</sup> The most common form of ingestion were cannabis resin, followed by cookies and joints.<sup>57</sup> Other exposures to cannabis included passive smoke, candies, beverages, and hemp oil. The most common sign of cannabis ingestion was lethargy. Ataxia, mydriasis, hypotonia, and tachycardia were also common presenting signs.<sup>57</sup>

## NEW WAYS TO USE

The traditional method of marijuana consumption has been to smoke the dry leaves of the plant. A joint is dried marijuana leaves rolled in cigarette paper. Blunts are marijuana leaves rolled in a hollowed-out cigar. Adolescent users may prefer blunts to joints because blunts hold a larger quantity of marijuana and burn slower. However, use of blunts is a health concern because of the co-use of cannabis and tobacco. In a study by Fairman,<sup>58</sup> the author found that blunt users had higher severity of current cannabis use-related problems, reporting more tolerance as well as spending more time getting, using, and getting over the effects of cannabis. Because of dual use of tobacco and cannabis in blunts, there is concern that those trying to quit smoking blunts could be at greater risk for relapse because of nicotine withdrawal symptoms.<sup>58</sup>

Other forms of marijuana available for consumption include hashish (a plant extract containing psychoactive resins), hash oil (cannabis concentrate extracted from hashish), and dabs (also cannabis concentrate). THC content varies but is generally much higher than concentrations found in the plant. Typical THC content of the marijuana plant ranges from 12% to 20%. Products produced by using solvents (butane hash oil and dabs) have THC content ranging from 39% to 80%.<sup>59</sup> Nonsolvent-produced concentrates have THC concentrations between 39% and 60%.

Marijuana is also available as vaporizable cannabis concentrates, as edibles, or as liquids. Vaporizable concentrates include "shatter" (a brittle, translucent material made from marijuana plant materials and solvents), "oil," wax, and "butane hash." Vaporizable cannabis concentrates contain 60% to 85%

THC, contain higher concentrations (compared with dried-leaf products), and can be consumed through vape pens, e-cigarettes, and dabs.<sup>60</sup> Dabs are concentrated butane hash oil consumed when the concentrate is heated to high temperatures and the user inhales the resulting vapor. In one study by Loflin and Earleywine,<sup>61</sup> the authors examined why users preferred dabs and examined whether dab use was associated with more problems than traditional cannabis use. Study participants reported that dabs required fewer hits to achieve desired effects. Study participants did not feel that their use was associated with more problems, but dab use was more likely to lead to dependence and withdrawal.<sup>61</sup>

E-cigarettes have been advertised as safe and healthier than traditional cigarettes; sales of these devices have targeted adolescents. The 2011–2018 National Youth Tobacco Survey and the Monitoring the Future survey both identified increases in e-cigarette use in middle and high school students compared with other tobacco products.<sup>62,63</sup> Eggers et al<sup>64</sup> explored use of cannabis through e-cigarette systems; cannabis use through e-cigarettes was higher among 11th-graders than ninth-graders and among youth with worse grades. In this study, the authors also found that use of cannabis through e-cigarettes (versus smoking blunts) had similar adverse effects on school performance. Both e-cigarette delivery of cannabis and blunt use were associated with greater tobacco use.<sup>64</sup> Physicians should consider methods of delivery when discussing cannabis use because e-cigarettes are a novel route of administration and appeal to youth who are not otherwise susceptible to cannabis via blunts or joints. The AAP 2015 policy statement on electronic nicotine delivery systems strongly recommends that pediatricians screen for and discourage vaping device use.<sup>65</sup>

## SCS

SCs, (eg, Spice and K2) have become popular recreational substances among young adults. These substances are plant-derived material adulterated with substances similar to synthetic THC. These are readily available for purchase online or in shops specializing in marijuana and tobacco paraphernalia. SCs are often marketed as safe, natural, herbal blends not intended for human consumption in attractive packaging. However, these products are not naturally produced. They are typically mass produced outside of the United States. They are typically dissolved and mixed with dried vegetation in an imprecise process. The dosing of one product batch can vary greatly from that of another batch. These products can also be contaminated with heavy metals, bacteria, and chemicals. For example, in 2018, 70 individuals experienced serious drug overdose in Connecticut from using synthetic cannabis that was contaminated with rat poison. Unlike THC, which is a partial agonist at CB1 and CB2 receptors, SCs are full agonists at CB1 and CB2 sites, increasing the potency of SCs.<sup>66</sup> This may account for the increased morbidity and mortality seen with the use of SCs compared with marijuana.<sup>67</sup>

Serious adverse health effects have been documented with the use of SCs. Adverse effects include cardiac abnormalities, coagulopathies, and neurologic and psychiatric abnormalities.<sup>68</sup> Cardiac effects include tachycardia and acute myocardial infarction.<sup>69,70</sup> A cardiac fatality was reported in a young adult after smoking SCs.<sup>71</sup> Hematologic abnormalities due to long-acting vitamin K-dependent antagonist contamination of SCs have been reported.<sup>71</sup> In a review of SC use, reports of acute kidney injury were noted. All individuals required hospitalization, and one individual required dialysis.<sup>72</sup> Neurologic abnormalities are also well

documented. SCs have been linked to strokes, seizures, and psychiatric effects, including anxiety, agitation, suicidal ideation, and psychosis. The neuropsychologic effects of SCs, compared with marijuana, are enhanced because of the difference in SC action at CB1 and CB2 sites.

There can be significant variation in SC potency, which can lead to serious adverse health events. These compounds can be mixed with other psychoactive substances, (eg, ecstasy, bath salts, and others). SC detection is often difficult in medical settings, and typical drug screening is often not helpful. Providers should be aware of possible adverse side effects of SC and should have a high index of suspicion when patients present with symptoms that could be due to consumption of SCs.

## MARIJUANA AND THE MEDIA

In 2019, marijuana was legal in 33 states for medical use and in 11 states for recreational use by adults. As legalization has increased, more and more information has appeared in mainstream press and social media discussing the benefits and risks of marijuana. Reports include discussion of different strains of marijuana plants, health benefit claims, adverse effects, where to purchase marijuana, how to obtain medical certification, where to use marijuana, and other topics. Thus, pediatricians should be aware of the information about marijuana use being disseminated through the media. Marijuana can be obtained through dispensaries for medicinal purposes with appropriate certification. Generally, patients need to consult with a physician and need to have a qualifying condition (which varies in different states). Depending on the state, they may be given an identification card, which allows them to purchase marijuana at a medical dispensary. The amount an individual may possess or purchase also varies by state. Medicaid and Medicare will

not pay for medicinal marijuana because the federal government prohibits the sale of schedule I drugs.

In general, consumers aged 21 years or older can purchase marijuana legally from recreational dispensaries. Although many cannabis purchases occur through traditional illegal face-to-face sales, cannabis products can also be purchased online, both through legal recreational use sales and illegal drug markets on the dark Web. Recreational sales are cash only in most states. Prices vary by product type, weight, and location of the sale. For example, a sativa-hybrid dried plant bought online costs \$60 per 3.5 g, and indica dried leaf bought from a recreational dispensary costs \$18 per gram.

A variety of marijuana products are available in recreational and medical dispensaries. Retail shops may display menus listing THC content, cannabis strain, and the mood or symptom relief it may provide. For example, Afgoeey (indica strain), has 22.9% THC and is advertised as "manageable psychoactivity and a wide range of applications, including pain relief and sedation."<sup>73</sup> Although different strains may be advertised as sedating or invigorating, there is no scientific evidence to support these claims. These aspects of a product may be due to other components of the plant, such as terpene content.<sup>74,75</sup> Further research is needed to accurately describe the effects of specific products.

Many people purchase medical and recreational marijuana online. In a 2017 *JAMA* study, authors found that nearly 70% of CBD products sold online contained higher or lower concentrations of the drug than was on their label. Some CBD products contained significant amounts of THC. CBD products sold for vaping were mislabeled 88% of the time, and THC was detected in 18 of 84 samples, some with enough to produce

intoxication.<sup>76</sup> It is important to counsel patients and parents about the THC content in CBD products and to note that they lack regulation by the FDA. Pediatricians should also refer to individual state laws for further information concerning purchasing, use, and possession of marijuana.

## CANNABIS USE DISORDER

Monitoring the Future survey data suggest that most adolescents do not perceive marijuana use as harmful, addictive, or associated with withdrawal.<sup>77,78</sup> However, 8% to 12% of marijuana users will develop moderate to severe cannabis use disorders. Additionally, animal studies reveal that marijuana can prime the brain to the effects of other illicit substances. Although less clearly delineated in humans, according to the Substance Abuse and Mental Health Services Administration, 4.2 million people in the United States had cannabis use disorder in 2017. The *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition* defines cannabis use disorder as use of cannabis for at least 1 year with the presence of 1 or 2 other findings consistent with addiction and significant impairment of functioning and distress.<sup>79</sup> Although cannabis use can negatively impact the user's health, to date it has not been linked to fatal overdoses.<sup>80-82</sup> In addition, individuals can experience cannabis withdrawal. **The *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition* describes cannabis withdrawal as having  $\geq 3$  of the following signs and symptoms within the 1 week of discontinuing use: (1) irritability, anger, or aggression; (2) nervousness or anxiety; (3) sleep difficulty or insomnia; (4) decreased appetite or weight loss; (5) restlessness; (6) depressed mood; and (7) at least 1 of the following: abdominal pain, shakiness or tremors, sweating, fever, chills, or headache.**<sup>79</sup>

Being young, having a lower socioeconomic status, male sex, and being a minority increases the risk of developing cannabis use disorder.<sup>83</sup>

Several treatments have been investigated for treatment of cannabis use disorder. In a review by Brezing and Levin,<sup>84</sup> the authors found several medication treatments that may be of benefit. Only one study was focused on treating adolescents: topiramate reduced marijuana use in adolescents but was not well tolerated.<sup>85</sup> In adult studies, gabapentin has been found to reduce withdrawal, reduce cravings, and improve cognitive functioning. Dronabinol and nabilone were also found to improve withdrawal symptoms and reduce cannabis use.<sup>86,87</sup> Nabilone plus zolpidem also improved withdrawal symptoms and reduced cannabis use.<sup>88</sup> Limitations to the current studies include inclusion of individuals with severe cannabis use disorder and high attrition rates. Brezing and Levin<sup>84</sup> note that reduction in use, rather than abstinence, may be an appropriate goal for treatment of cannabis use disorder. However, there is no consensus in the literature defining a meaningful reduction in use. Although research on medications for cannabis use disorder continues; motivational and cognitive behavioral therapies continue to be the mainstays of treatment at this time.

## CONCLUSIONS

Marijuana is one of the most commonly used psychoactive substances. The literature reveals a number of health concerns associated with marijuana use, from physical health effects to mental health effects, that can occur over the course of development and social consequences associated with use. It is important for providers to be aware of policies and laws around marijuana in their states to provide appropriate and evidenced-based

recommendations and to counsel appropriately to prevent exposure and thus harm to developing brains. The health and well-being of children and adolescents should be prioritized when providing this information. More research is needed on the long-term effects of marijuana and should also be focused on prevention of use in adolescents.

## ABBREVIATIONS

AAP: American Academy of Pediatrics  
CBD: cannabidiol  
e-cigarette: electronic cigarette  
FDA: US Food and Drug Administration  
IBD: inflammatory bowel disease  
SC: synthetic cannabinoid  
THC: tetrahydrocannabinol

## REFERENCES

1. ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC. Changes in cannabis potency over the last 2 decades (1995–2014): analysis of current data in the United States. *Biol Psychiatry*. 2016;79(7):613–619
2. Kann L, McManus T, Harris WA, et al. Youth risk behavior surveillance - United States, 2017. *MMWR Surveill Summ*. 2018;67(8):1–114
3. Han B, Compton WM, Blanco C, DuPont RL. National trends in substance use and use disorders among youth. *J Am Acad Child Adolesc Psychiatry*. 2017; 56(9):747–754.e3
4. Shi Y, Cummins SE, Zhu SH. Medical marijuana availability, price, and product variety, and adolescents' marijuana use. *J Adolesc Health*. 2018; 63(1):88–93
5. Foster BC, Abramovici H, Harris CS. Cannabis and cannabinoids: kinetics and interactions. *Am J Med*. 2019; 132(11):1266–1270
6. Lu HC, Mackie K. An introduction to the endogenous cannabinoid system. *Biol Psychiatry*. 2016;79(7):516–525

7. Ebbert JO, Scharf EL, Hurt RT. Medical cannabis. *Mayo Clin Proc*. 2018;93(12): 1842–1847
8. Manrique-Garcia E, Zammit S, Dalman C, Hemmingsson T, Andreasson S, Allebeck P. Prognosis of schizophrenia in persons with and without a history of cannabis use. *Psychol Med*. 2014;44(12): 2513–2521
9. Brzozowska NI, de Tonnerre EJ, Li KM, et al. The differential binding of antipsychotic drugs to the ABC transporter P-glycoprotein predicts cannabinoid-antipsychotic drug interactions. *Neuropsychopharmacology*. 2017; 42(11):2222–2231
10. Neale M. Efficacy and safety of cannabis for treating children with refractory epilepsy. *Nurs Child Young People*. 2017; 29(7):32–37
11. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Health Effects of Marijuana. *The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research*. Washington, DC: National Academies Press; 2017
12. Kurz R, Blaas K. Use of dronabinol (delta-9-THC) in autism: a prospective single-case-study with an early infantile autistic child. *Cannabinoids*. 2010;5(4): 4–6
13. Budney AJ, Hughes JR, Moore BA, Vandrey R. Review of the validity and significance of cannabis withdrawal syndrome. *Am J Psychiatry*. 2004; 161(11):1967–1977
14. Phatak UP, Rojas-Velasquez D, Porto A, Pashankar DS. Prevalence and patterns of marijuana use in young adults with inflammatory bowel disease. *J Pediatr Gastroenterol Nutr*. 2017;64(2):261–264
15. Elliott J, DeJean D, Clifford T, et al. Cannabis-based products for pediatric epilepsy: a systematic review. *Epilepsia*. 2019;60(1):6–19
16. Kaplan EH, Offermann EA, Sievers JW, Comi AM. Cannabidiol treatment for refractory seizures in Sturge-Weber syndrome. *Pediatr Neurol*. 2017;71: 18–23.e2



17. Gofshteyn JS, Wilfong A, Devinsky O, et al. Cannabidiol as a potential treatment for febrile infection-related epilepsy syndrome (FIRES) in the acute and chronic phases. *J Child Neurol*. 2017;32(1):35–40
18. Agrawal A, Budney AJ, Lynskey MT. The co-occurring use and misuse of cannabis and tobacco: a review. *Addiction*. 2012;107(7):1221–1233
19. Webster L, Chaiton M, Kirst M. The co-use of tobacco and cannabis among adolescents over a 30-year period. *J Sch Health*. 2014;84(3):151–159
20. Rubinstein ML, Rait MA, Prochaska JJ. Frequent marijuana use is associated with greater nicotine addiction in adolescent smokers. *Drug Alcohol Depend*. 2014;141:159–162
21. Brook JS, Lee JY, Brook DW. Trajectories of marijuana use beginning in adolescence predict tobacco dependence in adulthood. *Subst Abus*. 2015;36(4):470–477
22. Meruelo AD, Castro N, Cota CI, Tapert SF. Cannabis and alcohol use, and the developing brain. *Behav Brain Res*. 2017;325(pt A):44–50
23. Terry-McElrath YM, O'Malley PM, Johnston LD. Alcohol and marijuana use patterns associated with unsafe driving among US high school seniors: high use frequency, concurrent use, and simultaneous use. *J Stud Alcohol Drugs*. 2014;75(3):378–389
24. Hagan JF Jr., Shaw JS, Duncan PM, eds. *Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents*, 4th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2017
25. Committee on Substance Use and Prevention. Substance use screening, brief intervention, and referral to treatment. *Pediatrics*. 2016;138(1):e20161210
26. Boston Children's Hospital. About the CRAFFT. Available at: <https://craftt.org/about-the-craftt/>. Accessed August 6, 2019
27. Bose J, Hedden SL, Lipari RN, et al. *Key Substance Use and Mental Health Indicators in the United States: Results From the 2015 National Survey on Drug Use and Health*. Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2016
28. Brown QL, Sarvet AL, Shmulewitz D, Martins SS, Wall MM, Hasin DS. Trends in marijuana use among pregnant and nonpregnant reproductive-aged women, 2002–2014. *JAMA*. 2017;317(2):207–209
29. Young-Wolff KC, Tucker LY, Alexeeff S, et al. Trends in self-reported and biochemically tested marijuana use among pregnant females in California from 2009–2016. *JAMA*. 2017;318(24):2490–2491
30. Colorado Department of Public Health & Environment. Monitoring health concerns related to marijuana in Colorado: 2018 summary. Available at: <https://drive.google.com/file/d/1cyaRNiT7fUVD2VMb91ma5bLMuvtc9jZy/view>. Accessed June 12, 2020
31. Gunn JK, Rosales CB, Center KE, et al. Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis. *BMJ Open*. 2016;6(4):e009986
32. Mato S, Del Olmo E, Pazos A. Ontogenetic development of cannabinoid receptor expression and signal transduction functionality in the human brain. *Eur J Neurosci*. 2003;17(9):1747–1754
33. Benevenuto SG, Domenico MD, Martins MA, et al. Recreational use of marijuana during pregnancy and negative gestational and fetal outcomes: an experimental study in mice. *Toxicology*. 2017;376:94–101
34. Metz TD, Borgelt LM. Marijuana use in pregnancy and while breastfeeding. *Obstet Gynecol*. 2018;132(5):1198–1210
35. Conner SN, Bedell V, Lipsey K, Macones GA, Cahill AG, Tuuli MG. Maternal marijuana use and adverse neonatal outcomes: a systematic review and meta-analysis. *Obstet Gynecol*. 2016;128(4):713–723
36. Carter RC, Wainwright H, Molteno CD, et al. Alcohol, methamphetamine, and marijuana exposure have distinct effects on the human placenta. *Alcohol Clin Exp Res*. 2016;40(4):753–764
37. Sharapova SR, Phillips E, Sirocco K, Kaminski JW, Leeb RT, Rolle I. Effects of prenatal marijuana exposure on neuropsychological outcomes in children aged 1–11 years: a systematic review. *Paediatr Perinat Epidemiol*. 2018;32(6):512–532
38. Baker T, Datta P, Rewers-Felkins K, Thompson H, Kallum RR, Hale TW. Transfer of inhaled cannabis into human breast milk. *Obstet Gynecol*. 2018;131(5):783–788
39. Astley SJ, Little RE. Maternal marijuana use during lactation and infant development at one year. *Neurotoxicol Teratol*. 1990;12(2):161–168
40. Tennes K, Avitable N, Blackard C, et al. Marijuana: prenatal and postnatal exposure in the human. *NIDA Res Monogr*. 1985;59:48–60
41. Committee on Obstetric Practice. Committee opinion No. 722: marijuana use during pregnancy and lactation. *Obstet Gynecol*. 2017;130(4):e205–e209
42. Section on Breastfeeding. Breastfeeding and the use of human milk. *Pediatrics*. 2012;129(3). Available at: [www.pediatrics.org/cgi/content/full/129/3/e827](http://www.pediatrics.org/cgi/content/full/129/3/e827)
43. Rubino T, Realini N, Braida D, et al. Changes in hippocampal morphology and neuroplasticity induced by adolescent THC treatment are associated with cognitive impairment in adulthood. *Hippocampus*. 2009;19(8):763–772
44. Crews F, He J, Hodge C. Adolescent cortical development: a critical period of vulnerability for addiction. *Pharmacol Biochem Behav*. 2007;86(2):189–199
45. Meier MH, Caspi A, Ambler A, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. *Proc Natl Acad Sci U S A*. 2012;109(40):E2657–E2664
46. Camchong J, Lim KO, Kumra S. Adverse effects of cannabis on adolescent brain development: a longitudinal study. *Cereb Cortex*. 2017;27(3):1922–1930
47. Silins E, Horwood LJ, Patton GC, et al; Cannabis Cohorts Research Consortium. Young adult sequelae of adolescent cannabis use: an integrative analysis. *Lancet Psychiatry*. 2014;1(4):286–293
48. Rubino T, Parolaro D. Cannabis abuse in adolescence and the risk of psychosis: a brief review of the preclinical

- evidence. *Prog Neuropsychopharmacol Biol Psychiatry*. 2014;52:41–44
49. Di Forti M, Quattrone D, Freeman TP, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. *Lancet Psychiatry*. 2019;6(5):427–436
  50. Olfson M, Wall MM, Liu SM, Blanco C. Cannabis use and risk of prescription opioid use disorder in the United States. *Am J Psychiatry*. 2018;175(1):47–53
  51. Mack KA, Jones CM, Ballesteros MF. Illicit drug use, illicit drug use disorders, and drug overdose deaths in metropolitan and nonmetropolitan areas - United States. [published correction appears in *MMWR Surveill Summ*. 2017;66(45):1262]. *MMWR Surveill Summ*. 2017;66(19):1–12
  52. Keyes KM, Wall M, Cerdá M, et al. How does state marijuana policy affect US youth? Medical marijuana laws, marijuana use and perceived harmfulness: 1991–2014. *Addiction*. 2016;111(12):2187–2195
  53. Blohm E, Sell P, Neavyn M. Cannabinoid toxicity in pediatrics. *Curr Opin Pediatr*. 2019;31(2):256–261
  54. Sorensen CJ, DeSanto K, Borgelt L, Phillips KT, Monte AA. Cannabinoid hyperemesis syndrome: diagnosis, pathophysiology, and treatment - a systematic review. *J Med Toxicol*. 2017;13(1):71–87
  55. Dezieck L, Hafez Z, Conicella A, et al. Resolution of cannabis hyperemesis syndrome with topical capsaicin in the emergency department: a case series. *Clin Toxicol (Phila)*. 2017;55(8):908–913
  56. Wang GS, Le Lait MC, Deakyne SJ, Bronstein AC, Bajaj L, Roosevelt G. Unintentional pediatric exposures to marijuana in Colorado, 2009–2015. *JAMA Pediatr*. 2016;170(9):e160971
  57. Tai S, Fantegrossi WE. Pharmacological and toxicological effects of synthetic cannabinoids and their metabolites. *Curr Top Behav Neurosci*. 2017;32:249–262
  58. Fairman BJ. Cannabis problem experiences among users of the tobacco-cannabis combination known as blunts. *Drug Alcohol Depend*. 2015;150:77–84
  59. Meier MH, Docherty M, Leischow SJ, Grimm KJ, Pardini D. Cannabis concentrate use in adolescents. *Pediatrics*. 2019;144(3):e20190338
  60. Carlini BH, Garrett SB, Harwick RM. Beyond joints and brownies: marijuana concentrates in the legal landscape of WA State. *Int J Drug Policy*. 2017;42:26–29
  61. Loflin M, Earleywine M. A new method of cannabis ingestion: the dangers of dabs? *Addict Behav*. 2014;39(10):1430–1433
  62. Arrazola RA, Singh T, Corey CG, et al; Centers for Disease Control and Prevention (CDC). Tobacco use among middle and high school students - United States, 2011–2014. *MMWR Morb Mortal Wkly Rep*. 2015;64(14):381–385
  63. Cullen KA, Ambrose BK, Gentzke AS, Apelberg BJ, Jamal A, King BA. Notes from the field: use of electronic cigarettes and any tobacco product among middle and high school students - United States, 2011–2018. *MMWR Morb Mortal Wkly Rep*. 2018;67(45):1276–1277
  64. Eggers ME, Lee YO, Jackson K, Wiley JL, Porter L, Nonnemaker JM. Youth use of electronic vapor products and blunts for administering cannabis. *Addict Behav*. 2017;70:79–82
  65. Walley SC, Jenssen BP; Section on Tobacco Control. Electronic nicotine delivery systems. *Pediatrics*. 2015;136(5):1018–1026
  66. Aung MM, Griffin G, Huffman JW, et al. Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding. *Drug Alcohol Depend*. 2000;60(2):133–140
  67. Tait RJ, Caldicott D, Mountain D, Hill SL, Lenton S. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. *Clin Toxicol (Phila)*. 2016;54(1):1–13
  68. Davidson C, Opacka-Juffry J, Arevalo-Martin A, Garcia-Ovejero D, Molina-Holgado E, Molina-Holgado F. Spicing up pharmacology: a review of synthetic cannabinoids from structure to adverse events. *Adv Pharmacol*. 2017;80:135–168
  69. Keskin M, Hayiroğlu Mİ, Keskin Ü, Eren M. Acute myocardial infarction and ischemic stroke coexistence due to marijuana abuse in an adolescent. *Anatol J Cardiol*. 2016;16(7):542–543
  70. Shanks KG, Clark W, Behonick G. Death associated with the use of the synthetic cannabinoid ADB-FUBINACA. *J Anal Toxicol*. 2016;40(3):236–239
  71. Moritz E, Austin C, Wahl M, et al. Notes from the field: outbreak of severe illness linked to the vitamin K antagonist brodifacoum and use of synthetic cannabinoids - Illinois, March–April 2018. *MMWR Morb Mortal Wkly Rep*. 2018;67(21):607–608
  72. Buser GL, Gerona RR, Horowitz BZ, et al. Acute kidney injury associated with smoking synthetic cannabinoid. *Clin Toxicol (Phila)*. 2014;52(7):664–673
  73. The Apothecarium Dispensary. SOMA delivery and pickup menu. Available at: <https://apothecarium.com/soma-menu-heartjane>. Accessed June 12, 2020
  74. Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. *Br J Pharmacol*. 2011;163(7):1344–1364
  75. Komori T, Fujiwara R, Tanida M, Nomura J, Yokoyama MM. Effects of citrus fragrance on immune function and depressive states. *Neuroimmunomodulation*. 1995;2(3):174–180
  76. Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling accuracy of cannabidiol extracts sold online. *JAMA*. 2017;318(17):1708–1709
  77. The Monitoring the Future Study; University of Michigan. Figure 3: marijuana: trends in annual use, risk, disapproval, and availability: grades 8, 10, and 12. 2016. Available at: <http://www.monitoringthefuture.org/data/16data/16drfig3.pdf>. Accessed March 22, 2017
  78. The Monitoring the Future Study; University of Michigan. Figure 4: marijuana: trends in daily use, risk, disapproval, and availability: grades 8, 10, and 12. 2016. Available at: <http://www.monitoringthefuture.org/data/16data/16drfig3.pdf>. Accessed March 22, 2017
  79. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*, 5th ed. Washington,

- DC: American Psychiatric Association; 2013
80. Calabria B, Degehardt L, Hall W, Lynskey M. Does cannabis use increase the risk of death? Systematic review of epidemiological evidence on adverse effects of cannabis use. *Drug Alcohol Rev.* 2010;29(3):318–330
81. Budney AJ, Vandrey RG, Hughes JR, Thostenson JD, Bursac Z. Comparison of cannabis and tobacco withdrawal: severity and contribution to relapse. *J Subst Abuse Treat.* 2008;35(4):362–368
82. Hall W. Alcohol and cannabis: comparing their adverse health effects and regulatory regimes. *Int J Drug Policy.* 2017;42:57–62
83. Hasin DS, Kerridge BT, Saha TD, et al. Prevalence and correlates of DSM-5 cannabis use disorder, 2012–2013: findings from the National Epidemiologic Survey on Alcohol and Related Conditions-III. *Am J Psychiatry.* 2016;173(6):588–599
84. Brezing CA, Levin FR. The current state of pharmacological treatments for cannabis use disorder and withdrawal. *Neuropsychopharmacology.* 2018;43(1):173–194
85. Haney M, Ramesh D, Glass A, Pavlicova M, Bedi G, Cooper ZD. Naltrexone maintenance decreases cannabis self-administration and subjective effects in daily cannabis smokers. *Neuropsychopharmacology.* 2015;40(11):2489–2498
86. Levin FR, Mariani JJ, Brooks DJ, Pavlicova M, Cheng W, Nunes EV. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. *Drug Alcohol Depend.* 2011;116(1–3):142–150
87. Haney M, Cooper ZD, Bedi G, Vosburg SK, Comer SD, Foltin RW. Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse. *Neuropsychopharmacology.* 2013;38(8):1557–1565
88. Herrmann ES, Cooper ZD, Bedi G, et al. Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users. *Psychopharmacology (Berl).* 2016;233(13):2469–2478

## Marijuana and the Pediatric Population

Sadhana Dharmapuri, Kathleen Miller and Jonathan D. Klein

*Pediatrics* 2020;146;

DOI: 10.1542/peds.2019-2629 originally published online July 13, 2020;

### Updated Information & Services

including high resolution figures, can be found at:  
<http://pediatrics.aappublications.org/content/146/2/e20192629>

### References

This article cites 78 articles, 4 of which you can access for free at:  
<http://pediatrics.aappublications.org/content/146/2/e20192629#BIBL>

### Subspecialty Collections

This article, along with others on similar topics, appears in the following collection(s):

#### Substance Use

[http://www.aappublications.org/cgi/collection/substance\\_abuse\\_sub](http://www.aappublications.org/cgi/collection/substance_abuse_sub)

#### Addiction

[http://www.aappublications.org/cgi/collection/addiction\\_sub](http://www.aappublications.org/cgi/collection/addiction_sub)

### Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:

<http://www.aappublications.org/site/misc/Permissions.xhtml>

### Reprints

Information about ordering reprints can be found online:

<http://www.aappublications.org/site/misc/reprints.xhtml>

# American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN®





# PEDIATRICS<sup>®</sup>

OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF PEDIATRICS

## **Marijuana and the Pediatric Population**

Sadhana Dharmapuri, Kathleen Miller and Jonathan D. Klein

*Pediatrics* 2020;146;

DOI: 10.1542/peds.2019-2629 originally published online July 13, 2020;

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://pediatrics.aappublications.org/content/146/2/e20192629>

Pediatrics is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. Pediatrics is owned, published, and trademarked by the American Academy of Pediatrics, 345 Park Avenue, Itasca, Illinois, 60143. Copyright © 2020 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 1073-0397.

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN<sup>®</sup>

